title: Efficacy of leukocyte- and platelet-rich plasma gel (L-PRP gel) in treating osteomyelitis in a rabbit model.
abstract: Leukocyte- and platelet-rich plasma gel (L-PRP gel), a new autologous product which was previously utilized in several surgical procedures to enhance tissue healing, is now increasingly used as a promising treatment method for infections. In this study, we investigated the antibacterial property of L-PRP gel against Methicillin-resistive Staphylococcus aureus (MRSA, ATCC 43300) in a rabbit model of osteomyelitis. Tibial osteomyelitis was induced in 40 New Zealand white rabbits using the MRSA strain. Three weeks after induction, the rabbits with tibial osteomyelitis were randomly divided into four groups: Control group (no treatment); Van group (debridement and parenteral treatment with vancomycin alone); L-PRP gel + Van group (debridement and local L-PRP gel injection, plus parenteral treatment with vancomycin); L-PRP gel group (debridement and local L-PRP gel injection). All rabbits were sacrificed 6 weeks after debridement. The antibacterial efficacy was evaluated by radiological, microbiological, and histological examinations. Newly formed bone was also quantified. The best therapeutic efficacy, including infection elimination and bone defect repair, was observed in the L-PRP gel + Van group. Although not comparable to vancomycin, L-PRP gel also exibited antimicrobial efficacy in vivo. We believe that a combination of L-PRP gel and antibiotics could be a favorable alternative for the treatment of osteomyelitis.
authors.affiliation: Department of Orthopaedics, Shanghai Jiaotong University Affiliated Sixth People's Hospital, Shanghai 200233, China.
authors.forename: Guang-Yi
authors.initials: GY
authors.lastname: Li
authors.forename: Ji-Min
authors.initials: JM
authors.lastname: Yin
authors.forename: Hao
authors.initials: H
authors.lastname: Ding
authors.forename: Wei-Tao
authors.initials: WT
authors.lastname: Jia
authors.forename: Chang-Qing
authors.initials: CQ
authors.lastname: Zhang
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D004195:Disease Models, Animal; D004353:Drug Evaluation, Preclinical; D036341:Intercellular Signaling Peptides and Proteins / Q000097:blood; D007958:Leukocyte Count; D055624:Methicillin-Resistant Staphylococcus aureus / Q000187:drug effects*; D010019:Osteomyelitis / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy* / Q000382:microbiology; D053657:Platelet-Rich Plasma; D011817:Rabbits; D013203:Staphylococcal Infections / Q000178:diet therapy*; D013977:Tibia / Q000473:pathology; D014640:Vancomycin / Q000627:therapeutic use
chemical_list: D000900:Anti-Bacterial Agents; D036341:Intercellular Signaling Peptides and Proteins; D014640:Vancomycin